Floatz Rating
B59/100
Confidence
Indicative
Sponsor
University of Oklahoma
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
44High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05523440CT.gov Bevacizumab and/or Niraparib in Patients With Recurrent Endometrial and/or Ovarian Cancer With ARID1A Mutation | — | Terminated | — | — | — |
NCT05169437CT.gov Niraparib in the Treatment of Patients With Advanced PALB2 Mutated Tumors | — | Terminated | — | — | — |
NCT04178460CT.gov A Study of Niraparib Combined With MGD013 in Patients With Advanced or Metastatic Solid Tumor Who Failed Prior Treatment | — | Terminated | — | — | — |
NCT03586661CT.gov Niraparib and Copanlisib in Treating Patients With Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | — | Active Not Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Endometrial Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Niraparib (this asset) | University of Oklahoma | P2 | B · 59 |
| Indocyanine Green | Istanbul University | P4 | BB |
| Adriamycin | AstraZeneca | P3 | BB |
| Olaparib | Qilu Pharmaceutical Co., Ltd. | P4 | BB |
| Palbociclib | University Medical Center Groningen | P4 | BB |
| Nivestim | Mayo Clinic | P3 | B |
| Rilvegostomig | AstraZeneca | P3 | B |
| Capivasertib | M.D. Anderson Cancer Center | P2 | B |
| Cyclophosphamide | Sutro Biopharma, Inc. | P3 | B |
+42 more in the Endometrial Carcinoma cohort
Other indications for Niraparib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Breast Carcinoma | — | P3 | BB · 67 |
| Ovarian Carcinoma | — | P4 | BB · 66 |
| Ovarian Neoplasm | — | P4 | BB · 66 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Niraparib in Endometrial Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/niraparib-endometrial-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →